Charles River Laboratories International, Inc. (NYSE: CRL) Investor Investigation Over Potential Wrongdoing Announced

Investors who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL) shares have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Charles River Laboratories
Affected Securities: 
NYSE: CRL

An investigation on behalf of investors in shares of Charles River Laboratories International, Inc. (NYSE: CRL) was announced over potential breaches of fiduciary duties by certain officers and directors at Charles River Laboratories.

The investigation by a law firm concerns whether certain Charles River Laboratories International, Inc. directors breached their fiduciary duties.

Wilmington, MA based Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. Charles River Laboratories International, Inc. reported that its annual Total Revenue rose from over $1.68 billion in 2016 to over $1.85 billion in 2017 and that its Net Income declined from $156.36 million in 2016 to $125.44 million in 2017.

Shares of Charles River Laboratories International, Inc. (NYSE: CRL) rose from $67.20 per share in October 2016 to as high as $119.05 per share in October 2017.